KARD Stock Forecast: Kardigan, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Kardigan, Inc. hold a median 12-month price target of $43 — +115.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
KARD stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Kardigan, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (36): Smaller than most of the companies we track.
Volatility (3): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Kardigan, Inc. — and when they’d sell — is the membership.
KARD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KARD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +115.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | Jefferies | Initiates | Buy | $40 |
| 13 July 2026 | JP Morgan | Initiates | Overweight | $51 |
| 13 July 2026 | Leerink Partners | Initiates | Outperform | $37 |
| 13 July 2026 | TD Cowen | Initiates | Buy | $46 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KARD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Kardigan, Inc. (KARD) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −6.5×
- Price / sales
- —
- Price / book
- −4.3×
- EV / EBITDA
- −7.2×
Cheaper than 91% of US stocks
Cheaper than 96% of US stocks
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 76.7%
- Return on assets
- −49.1%
- Dividend yield
- —
Higher than 95% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
KARD vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KARD appears on the weeks it earns a place.
Frequently asked questions about KARD stock
What is the KARD stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Kardigan, Inc. have a median 12-month price target of $43, with estimates ranging from $37 to $51. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KARD stock a buy right now?
Of the 4 analysts covering Kardigan, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kardigan, Inc. 1 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KARD?
As at 1 Aug 2026, Kardigan, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (36 of 100).
Will KARD stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +115.3% from the last close, and Ticker Nerd's factor model ranks Kardigan, Inc. 1 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KARD stock forecast for 2030?
No analyst covering Kardigan, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $51 over the next 12 months.
What does Kardigan, Inc. do?
Kardigan, Inc. is a clinical-stage biotechnology company focused on cardiovascular drug development.
About Kardigan, Inc.
Kardigan, Inc. is a clinical-stage biotechnology company focused on cardiovascular drug development. It develops medicines aimed at the root causes of specific heart and vascular diseases, using patient data, clinical trial insights, and advanced analytics to identify responders and refine treatment strategies. The company’s work centers on targeted therapies for unmet needs in cardiology, including diseases where approved treatment options remain limited. Kardigan also combines internal research with licensing and collaborative development to build a portfolio of cardiovascular candidates. Based in South San Francisco, California, Kardigan operates as a heart health company serving the broader biopharmaceutical and healthcare ecosystem.
CEO Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA · 241 employees · United States · https://www.kardigan.bio